American Vanguard (AVD) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
The 2025 Annual Meeting will be held virtually on July 2, 2025, with voting on director elections, auditor ratification, and executive compensation approval.
Nine directors are nominated, including recent appointees, reflecting significant board refreshment and leadership changes over the past year.
The company underwent major transformation initiatives in 2024, including digital upgrades and leadership transitions, resulting in nonrecurring charges and a net loss.
No cash bonuses were awarded to executives for 2024 due to performance, and compensation remains below peer medians.
Shareholder engagement and feedback have influenced compensation and governance practices.
Voting matters and shareholder proposals
Shareholders will vote on electing nine directors, ratifying Deloitte & Touche LLP as auditor for 2025, and an advisory say-on-pay vote for executive compensation.
No additional shareholder proposals or director nominations were received for this meeting.
Voting can be conducted online, by phone, mail, or during the virtual meeting with a control number.
Board of directors and corporate governance
The board consists of nine members with diverse backgrounds in agribusiness, operations, legal, finance, and ESG.
Recent board refreshment includes new CEO Douglas Kaye III and new directors Steven Macicek and Carmen Tiu.
The roles of Chair and CEO are now separated, with an independent lead director overseeing board agendas.
Seven of nine nominees are independent under NYSE standards.
The board met 17 times in 2024, with all directors attending at least 75% of meetings.
Latest events from American Vanguard
- 2025 margins improved and losses narrowed; 2026 targets higher EBITDA and growth from new products.AVD
Q4 202516 Mar 2026 - Q2 sales and margins fell, guidance was cut, and transformation and cost-saving efforts accelerated.AVD
Q2 20242 Feb 2026 - Q3 loss and sales drop driven by recall, but guidance and non-crop growth remain strong.AVD
Q3 202415 Jan 2026 - Transformation plan aims for 15% EBITDA margin and growth in biologicals by 2025.AVD
Gabelli Funds' 16th Annual Specialty Chemicals Symposium26 Dec 2025 - 2024 EBITDA met guidance as debt and inventory fell; 2025 targets higher revenue and margin.AVD
Q4 202424 Dec 2025 - Adjusted EBITDA up 350%, gross margin 29%, and net loss narrowed on strong U.S. crop sales.AVD
Q3 202517 Nov 2025 - Q1 sales dropped 14% with a net loss, but cost cuts and lower debt support recovery.AVD
Q1 202514 Nov 2025 - Adjusted EBITDA nearly doubled and gross margin hit a five-quarter high as net loss narrowed.AVD
Q2 20257 Aug 2025